Steven MD - Carl Zeiss Chief Devices
| CZMWY Stock | USD 59.54 2.18 3.53% |
Insider
Steven MD is Chief Devices of Carl Zeiss Meditec
| Phone | 49 3641 220 115 |
| Web | https://www.zeiss.de/meditec-ag/home.html |
Carl Zeiss Management Efficiency
The company has return on total asset (ROA) of 0.0955 % which means that it generated a profit of $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1596 %, meaning that it generated $0.1596 on every $100 dollars invested by stockholders. Carl Zeiss' management efficiency ratios could be used to measure how well Carl Zeiss manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MAICSA FCIS | Top Glove | 65 | |
| Martin Wiechmann | Carl Zeiss Meditec | N/A | |
| Jacqueline Kunzler | Baxter International | 55 | |
| Amy McbrideWendell | Baxter International | 60 | |
| Aurelio Sahagun | Straumann Holding AG | 50 | |
| Ajay Kumar | Embecta Corp | 53 | |
| Marco Catalani | EssilorLuxottica Socit anonyme | N/A | |
| Teresa Madden | The Cooper Companies, | 65 | |
| Kensuke Lizuka | Sysmex Corp | N/A | |
| Warner H | The Cooper Companies, | 56 | |
| Vered Keisar | ResMed Inc | N/A | |
| Giorgio Iannella | EssilorLuxottica Socit anonyme | N/A | |
| Ellen Bjurgert | Coloplast A | N/A | |
| James Borzi | Baxter International | 61 | |
| WeiAnn Voon | Top Glove | N/A | |
| Kimberly MacKay | West Pharmaceutical Services | 58 | |
| Justin Leong | ResMed Inc | 47 | |
| Rajwant Sodhi | ResMed Inc | 46 | |
| Augustine JD | Hoya Corp | 55 | |
| Dennis Kaysen | Coloplast A | N/A | |
| Euan Thomson | Carl Zeiss Meditec | 60 | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0955 |
Carl Zeiss Meditec Leadership Team
Elected by the shareholders, the Carl Zeiss' board of directors comprises two types of representatives: Carl Zeiss inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carl. The board's role is to monitor Carl Zeiss' management team and ensure that shareholders' interests are well served. Carl Zeiss' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carl Zeiss' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sebastian Frericks, Director Investor Relations | ||
| Laurie Ferguson, Head Devices | ||
| Markus Weber, CEO Pres | ||
| Martin Wiechmann, Head Unit | ||
| Andrew Chang, I Meditec | ||
| Euan Thomson, Pres Unit | ||
| Steven MD, Chief Devices | ||
| Justus Wehmer, CFO, Member of the Management Board | ||
| Mike Wang, Head Shanghai |
Carl Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Carl Zeiss a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 12.07 B | |||
| Shares Outstanding | 89.44 M | |||
| Price To Earning | 78.84 X | |||
| Price To Book | 6.64 X | |||
| Price To Sales | 6.17 X | |||
| Revenue | 1.9 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Carl Pink Sheet Analysis
When running Carl Zeiss' price analysis, check to measure Carl Zeiss' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carl Zeiss is operating at the current time. Most of Carl Zeiss' value examination focuses on studying past and present price action to predict the probability of Carl Zeiss' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carl Zeiss' price. Additionally, you may evaluate how the addition of Carl Zeiss to your portfolios can decrease your overall portfolio volatility.